Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016', provides in depth analysis on Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - The report reviews Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics and enlists all their major and minor projects - The report assesses Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Overview 7 Therapeutics Development 8 Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Stage of Development 8 Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Therapy Area 9 Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Indication 10 Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Companies 14 Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Universities/Institutes 16 Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Companies Involved in Therapeutics Development 25 Cleveland BioLabs, Inc. 25 Neuropore Therapies, Inc. 26 Opsona Therapeutics Limited 27 Vascular Biogenics Ltd. 28 Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Drug Profiles 29 CBLB-612 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 CBLB-613 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 DMT-200 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 DMT-210 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 DMT-220 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 infectious vaccine - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 OPN-305 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 P-13 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 P-MAPA - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecules to Agonize TLR2 for Neurodegenerative Diseases - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecules to Antagonize TLR-1 and TLR-2 for Infectious Disease and Neuroinflammation - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecules to Antagonize TLR2 and TLR4 for Immune inflammatory Diseases - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 SP-16 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Synthetic Peptide to Target PPAR-Gamma and TLR-2 and IBD and Tissue Injury - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Vaccine to Target MUC-1 and TLR-2 for Breast Cancer - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 VB-201 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Dormant Projects 51 Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Discontinued Products 54 Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Featured News & Press Releases 55 May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study 55 Jan 26, 2016: Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation 55 Jul 13, 2015: Cleveland BioLabs Announces Results of Phase 1 Study of CBLB612 in Russian Federation 56 Apr 02, 2015: Cleveland BioLabs Announces New U.S. Composition of Matter Patent for CBLB612 56 Mar 16, 2015: Cleveland BioLabs Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation 57 Mar 02, 2015: Opsona Therapeutics commences Part B of phase II study of Blocking Toll-Like Receptor 2 in Extended Criteria Donor renal transplant recipients at high risk of Early Graft Dysfunction 57 Feb 23, 2015: Opsona Therapeutics Patent issued in USA covering an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof 57 Feb 18, 2015: Opsona Therapeutics Patent issued in US and EU covering the Opsona-developed antibody OPN-305, which is directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof 58 Feb 17, 2015: VBL Therapeutics Reports Topline Results From Phase 2 Studies of VB-201 in Psoriasis and Ulcerative Colitis 59 Feb 09, 2015: VBL Therapeutics to Present Preclinical Data at Keystone Symposium on Liver Metabolism and Nonalcoholic Fatty Liver Disease 60 Feb 06, 2015: VBL Therapeutics Receives European Patent Issuance on Lecinoxoid Platform Technology 61 Jan 29, 2015: VBL Therapeutic In Cooperation With KCR Reported LPO In Phase 2 Of VB-201 61 Jan 27, 2015: Opsona Therapeutics initiates phase I / II prospective open in patients with myelodysplastic syndrome second line of lower level (low and intermediate-1) with OPN-305 label ... 62 Jan 27, 2015: Opsona Therapeutics OPN-305 examines pretreatment myelodysplasia 62 Jan 26, 2015: Opsona Therapeutics initiates a prospective open label Phase I/II study in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS) with OPN-305, a First-in Class Monoclonal 62 Appendix 64 Methodology 64 Coverage 64 Secondary Research 64 Primary Research 64 Expert Panel Validation 64 Contact Us 64 Disclaimer 65
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Assessment by Monotherapy/Combination Products, H2 2016 18 Number of Products by Stage and Mechanism of Action, H2 2016 20 Number of Products by Stage and Route of Administration, H2 2016 22 Number of Products by Stage and Molecule Type, H2 2016 24 Pipeline by Cleveland BioLabs, Inc., H2 2016 25 Pipeline by Neuropore Therapies, Inc., H2 2016 26 Pipeline by Opsona Therapeutics Limited, H2 2016 27 Pipeline by Vascular Biogenics Ltd., H2 2016 28 Dormant Projects, H2 2016 51 Dormant Projects (Contd..1), H2 2016 52 Dormant Projects (Contd..2), H2 2016 53 Discontinued Products, H2 2016 54
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
